The story of Viagra presents a nuanced case for investors in the medicinal sector. While initially a tremendous success, creating vast sums, the intellectual property end and the subsequent flood of off-brand alternatives have drastically changed earnings. This raises questions about the long-term viability of analogous therapeutic innovations a… Read More